Ideaya Biosciences initiates expansion in IDE397 trial

Ideaya Biosciences (IDYA) announced the initiation of a Phase 1/2 expansion in the clinical trial evaluating IDE397, its investigational, small molecule methionine adenosyltransferase 2a inhibitor, in combination with Gilead’s (GILD) Trodelvy, a Trop-2 directed antibody-drug conjugate, in methylthioadenosine phosphorylase-deletion urothelial cancer based on preliminary safety and clinical efficacy data. Pursuant to the clinical study collaboration and supply agreement, IDEAYA and Gilead retain the commercial rights to their respective compounds, including with respect to use as a monotherapy or combination agent. IDEAYA is the study sponsor and Gilead will provide the supply of Trodelvy to IDEAYA.